http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Dam Kim ),( Soo-kyung Cho ),( Seoung Wan Nam ),( Hyuk Hee Kwon ),( Sun-young Jung ),( Chan Hong Jeon ),( Seul Gi Im ),( Dalho Kim ),( Eun Jin Jang ),( Yoon-kyoung Sung ) 대한류마티스학회 2017 대한류마티스학회지 Vol.24 No.5
Objective. To estimate the cardiovascular (CV) and gastrointestinal (GI) risks of etoricoxib in the treatment of osteoarthritis (OA) compared to a placebo and other non-steroidal anti-inflammatory drugs (NSAIDs). Methods. A systematic review of randomized, controlled trials (RCTs) of etoricoxib were performed. Bayesian network meta-analysis was used over a duration of 12 weeks. The incidence of CV and GI events for a duration ≥26 weeks were also tabulated and presented using descriptive statistics. Results. From this search, 10 studies were identified. Of these, 6 and 5 RCTs that measured the CV and GI events at 12 weeks were included in meta-analysis. They showed that etoricoxib did not increase the CV events compared to the placebo or NSAIDs during the 12 week period (odds ratio [OR]=0.59 compared to celecoxib, OR=0.89 with ibuprofen, OR=0.70 with placebo, and OR=2.16 with naproxen). The risk of GI events was comparable to that of most comparators, with the exception of naproxen, which had a significantly lower risk of GI events (OR=0.18) during the 12 week period. For a duration ≥26 weeks, the incidence of CV and GI events with etoricoxib increased with increasing duration. Conclusion. Etoricoxib is an alternative short-term treatment option for OA, showing comparable CV and GI complications to other NSAIDs. Nevertheless, further studies will be needed to elucidate the long-term safety of etoricoxib in the treatment of OA. (J Rheum Dis 2017;24:293-302)
Seul Gi Park,Eun-kyoung Kim,Hyoung-Chin Kim,Won-Kee Yoon,Ki-Hoan Nam,Sang-Yoon Nam 한국실험동물학회 2021 한국실험동물학회 학술발표대회 논문집 Vol.2021 No.7
Asb2, ankyrin repeat and SOCS box protein 2 form an E3 ubiquitin ligase complex. Asb2 ubiquitin ligase activity drives the degradation of filamins, which have essential functions in humans [1, 2]. The placenta is a temporary organ that is formed during pregnancy, and normal placentation is important for survival and growth of the fetus [3]. Recent studies have shown that approximately 25-30% of knockout (KO) mice have non-viable offspring, and 68% of knockout lines exhibit placental dysmorphologies [4]. There are very few studies on Asb2, with insufficient researches on its role in placental development. We generated Asb2 knockout mice and investigated Asb2 expression during organogenesis, and identified its role in early embryonic and placental development. The external morphology of KO embryos revealed abnormal phenotypes including growth retardation, peri-cardial effusion, pale color, and especially heart beat defect from E 9.5. Furthermore, Asb2 expression was observed in the heart from E 9.5, indicating that it is specifically expressed during early heart formation and defects, result in embryonic lethality. Histological analysis of E 10.5 KO mouse heart showed malformations such as failure of chamber formation, reduction in trabeculated myocardium length, absence of mesenchymal cells, and destruction of myocardial wall. Moreover, the histological observation of the placenta for Asb2-deficient mice showed abnormal phenotypes including small labyrinth and reduced vascular complexity, indicating that failure to establish mature circulatory pattern affects the embryonic development and associated with the early mortality. Collectively, our results demonstrate that Asb2 knockout mice have placental defects, and failure to form a normal cardiac septum, and thereby result in embryonic lethality in utero at around E 9.5. References [1] Babon, J.J., et al., The SOCS box domain of SOCS3: structure and interaction with the elonginBC-cullin5 ubiquitin ligase. J Mol Biol, 2008. 381(4): p. 928-40.[2] Heuze, M.L., et al., ASB2 is an Elongin BC-interacting protein that can assemble with Cullin 5 and Rbx1 to reconstitute an E3 ubiquitin ligase complex. J Biol Chem, 2005. 280(7): p. 5468-74.[3] Cross, J.C., D.G. Simmons, and E.D. Watson, Chorioallantoic morphogenesis and formation of the placental villous tree. Ann N Y Acad Sci, 2003. 995: p. 84-93.[4] Rossant, J. and J.C. Cross, Placental development: lessons from mouse mutants. Nat Rev Genet, 2001. 2(7): p. 538-48.
Beware of Early Relapse in Rectal Cancer Patients Treated With Preoperative Chemoradiotherapy
Seul Gi Oh,박인자,Ji-hyun Seo,Young Il Kim,Seok-Byung Lim,Chan Wook Kim,Yong Sik Yoon,Jong Lyul Lee,Chang Sik Yu,Jin Cheon Kim 대한대장항문학회 2020 Annals of Coloproctolgy Vol.36 No.6
Purpose: Recurrence patterns in rectal cancer patients treated with preoperative chemoradiotherapy (PCRT) are needed to evaluate for establishing tailored surveillance protocol. Methods: This study included 2,215 patients with locally-advanced mid and low rectal cancer treated with radical resection between January 2005 and December 2012. Recurrence was evaluated according to receipt of PCRT; PCRT group (n = 1,258) and no-PCRT group (n = 957). Early recurrence occurred within 1 year of surgery and late recurrence after 3 years. The median follow-up duration was 65.7 ± 29 months. Results: The overall recurrence rate was similar between the PCRT and no-PCRT group (25.8% vs. 24.9%, P = 0.622). The most common initial recurrence site was the lungs in both groups (50.6% vs. 49.6%, P = 0.864), followed by the liver, which was more common in the no-PCRT group (22.5% vs. 33.6%, P = 0.004). Most of the recurrence occurred within 3 years after surgery in both groups (85.3% vs. 85.8%, P = 0.862). Early recurrence was more common in the PCRT group than in the no-PCRT group (43.1% vs. 32.4%, P = 0.020). Recurrence within the first 6 months after surgery was significantly higher in the PCRT group than in the no-PCRT group (18.8% vs. 7.6%, P = 0.003). Lung (n = 27, 44.3%) and liver (n = 22, 36.1%) were the frequent the first relapsed site within 6 months after surgery in PCRT group. Conclusion: Early recurrence within the first 1 year after surgery was more common in patients treated with PCRT. This difference would be considered for surveillance protocols and need to be evaluated in further studies.